drugset / Trial / NCT01912391

Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder

NCT01912391

Phase 3 Completed 30 enrolled Mood and Anxiety Research, Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

Selegiline is superior to placebo in improving psychological and physical functioning in patients with Borderline Personality Disorder.

Timeline

Start
2012-10
Primary completion
2015-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Selegiline Unknown 12 mg Other